Today: 29 April 2026
Browse Category

NYSE:RHHBY 17 July 2025 - 16 September 2025

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly will invest $5 billion to build a 200,000-square-foot drug manufacturing plant in Goochland County, Virginia, creating 650 permanent jobs and 1,800 construction jobs. The facility will produce active pharmaceutical ingredients for cancer and autoimmune treatments. The project is part of Lilly’s $27 billion U.S. expansion plan. Virginia approved over $10 million in incentives to secure the site.
16 September 2025
·······
Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Genentech is ending its $2 billion cell therapy partnership with Adaptive Biotechnologies, citing cost-cutting but no safety issues. Kriya Therapeutics raised $313 million in Series D funding, one of the year’s largest biotech rounds. The FDA delayed Neurizon’s ALS drug trial review until October due to staffing shortages. Stealth BioTherapeutics has resubmitted its elamipretide application for Barth syndrome after two FDA rejections.
19 August 2025
····
AI Pathology Breakthrough: Roche’s Lung Cancer Diagnostic Makes FDA History

AI Pathology Breakthrough: Roche’s Lung Cancer Diagnostic Makes FDA History

Roche’s Ventana TROP2 (EPR20043) RxDx test became the first AI-powered diagnostic to receive FDA Breakthrough Device Designation in April 2025. The system uses digital pathology and AI to classify NSCLC tumors as TROP2-positive or negative, guiding use of Datopotamab deruxtecan. In a retrospective analysis, TROP2-positive patients saw a 43% lower risk of progression or death with the drug versus chemotherapy.
17 July 2025
·

Stock Market Today

  • US Stocks Slip as Oil Prices Surge, Tech Shares Weigh on Market
    April 29, 2026, 10:27 AM EDT. US stocks edged lower with the S&P 500 down 0.2%, retreating after recent all-time highs. The Dow Jones fell 97 points, also 0.2%, while the Nasdaq Composite declined 0.4%. Artificial intelligence stocks led the losses amid growing concerns over surging oil prices, which are adding pressure on market sentiment. Investors remain cautious as higher energy costs raise fears over inflation and corporate earnings. The pullback signals a pause following tech-driven gains, highlighting how energy price volatility continues to influence trading dynamics.

Latest article

Enphase Energy, Inc. Stock Slides as Q1 Reveals a Solar Demand Hangover

Enphase Energy, Inc. Stock Slides as Q1 Reveals a Solar Demand Hangover

29 April 2026
Enphase Energy shares dropped 7.3% to $31.80 after reporting a first-quarter revenue decline to $282.9 million and a GAAP loss of $7.4 million. U.S. revenue fell 23% from the prior quarter, with sell-through demand down 48% sequentially. Adjusted earnings beat estimates, but investors appeared unconvinced demand had stabilized. SolarEdge and Sunrun shares also fell in early trading.
Western Digital Stock Jumps Before Earnings as AI Storage Demand Gets a Seagate Boost

Western Digital Stock Jumps Before Earnings as AI Storage Demand Gets a Seagate Boost

29 April 2026
Western Digital shares rose 9.3% to $427.45 Wednesday after Seagate’s quarterly forecast topped estimates and sent storage stocks higher. Seagate shares jumped 16.6%. Seagate projected fourth-quarter revenue of $3.45 billion and non-GAAP earnings of $5 a share. Western Digital will report fiscal third-quarter results after markets close Thursday.
Generac Stock Jumps After Data Center Backlog Forces a 2026 Forecast Reset

Generac Stock Jumps After Data Center Backlog Forces a 2026 Forecast Reset

29 April 2026
Generac Holdings raised its 2026 sales outlook after first-quarter net sales rose 12% and commercial and industrial sales jumped 28% to $510 million, driven by data center demand. Shares climbed 11% after adjusted earnings of $1.80 a share beat estimates. The company now expects full-year net sales growth in the mid-to-high teens percentage range, up from its prior forecast. Generac also increased its adjusted EBITDA margin guidance.
Go toTop